bioMérieux and Specific Diagnostics announce a co-exclusive distribution agreement for the SPECIFIC REVEAL® Rapid AST system in Europe prweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prweb.com Daily Mail and Mail on Sunday newspapers.
bioMérieux Announces the CE Marking of NEPHROCHECK Test on VIDAS
in assay to detect kidney stress in patients at risk of acute kidney injury (AKI).
AKI is a common complication, affecting between 7 and 18% of all hospitalized patients
1 and up to 50% of critically ill patients
2. The condition is associated with a 10-fold increase in hospital mortality and a higher rate of chronic kidney disease among post-op patients
3
While a number of acute risk factors and patient characteristics have been identified which predispose patients to AKI
4, there is no reliable way for a clinician to establish a clear risk profile for any given patient.
bioMérieux Announces the CE Marking of Its Molecular Biology ARGENE Test for the Simultaneous Detection of SARS-CoV-2, Influenza Viruses A and B, and RSV and hMPV Viruses
in vitro diagnostics, has announced the expansion of its ARGENE range for the real-time PCR (RT-PCR) detection of SARS-CoV-2: the SARS-COV-2 RESPI R-GENE test has received CE marking and is now commercially available.
This high-throughput test, which can be used on molecular biology platforms in hospital laboratories and private laboratories, allows the simultaneous (multiplex) detection of SARS-CoV-2 and influenza viruses A and B. In addition, it includes a cellular control to check the quality of the sample, providing an important clinical advantage in the context of the pandemic and large-scale sample collection at many different sites. In a single kit, this new test comes with a second RT-PCR analysis performed from the same extraction, for the detection of two other pathogens that often circulate at the